Skip to main content

Peer Review reports

From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Original Submission
17 Feb 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
2 Aug 2012 Reviewed Reviewer Report - Yutaka Seino
9 Aug 2012 Reviewed Reviewer Report - Mark Fineman
14 Sep 2012 Reviewed Reviewer Report - David Boulton
13 Nov 2012 Author responded Author comments - Elizabeth Hussey
Resubmission - Version 3
13 Nov 2012 Submitted Manuscript version 3
18 Jan 2013 Author responded Author comments - Elizabeth Hussey
Resubmission - Version 4
18 Jan 2013 Submitted Manuscript version 4
24 Jan 2013 Reviewed Reviewer Report - David Boulton
11 Feb 2013 Reviewed Reviewer Report - Mark Fineman
13 Feb 2013 Reviewed Reviewer Report - Yutaka Seino
19 Mar 2013 Author responded Author comments - Elizabeth Hussey
Resubmission - Version 5
19 Mar 2013 Submitted Manuscript version 5
9 Apr 2013 Reviewed Reviewer Report - Yutaka Seino
11 Apr 2013 Author responded Author comments - Elizabeth Hussey
Resubmission - Version 6
11 Apr 2013 Submitted Manuscript version 6
Publishing
12 Apr 2013 Editorially accepted
13 May 2013 Article published 10.1186/2050-6511-14-26

You can find further information about peer review here.

Back to article page